Study guide
8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
Key Takeaways Explain This Topic AI
The KDOQI 2020 Clinical Practice Guideline recommends an energy prescription of 25 to 35 kcal/kg body weight/day for adults with CKD Stages 3–5D who are metabolically stable, adjusted for age, sex, physical activity, body composition, and weight goals.
Providing adequate non-protein energy is a mandatory physiological prerequisite for protein sparing; if caloric intake drops below 25 kcal/kg/day, dietary and endogenous amino acids are oxidized via gluconeogenesis, exacerbating nitrogenous retention and precipitating muscle wasting.
In patients with obesity (BMI > 30 kg/m²), calculating energy requirements using actual body weight induces severe hypercaloric overfeeding; clinicians commonly use an adjusted body weight (for example, aBW = IBW + 0.25 × [Actual − IBW]) to calculate caloric prescriptions.
A dietary fiber intake of 25 to 30 g/day supports colonic saccharolytic fermentation, enhances short-chain fatty acid (SCFA) generation, and suppresses the bacterial synthesis of potent cardiorenal uremic toxins including indoxyl sulfate and p-cresyl sulfate.
The Plant-Dominant Low-Protein Diet (PLADO) protocol prescribes 0.6 to 0.8 g protein/kg/day with 50% to 70% from whole unrefined plant foods, yielding lower dietary acid load (PRAL), reduced phosphorus bioavailability (phytate binding), and preserved glomerular hemodynamics.
Last updated: September 2026
Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
Core Clinical Practice Standard: For metabolically stable adults across the CKD continuum (Stages 3–5 and 5D), the KDOQI 2020 Clinical Practice Guideline recommends an energy intake of 25 to 35 kcal per kilogram body weight per day , tailored to age, sex, physical activity level, and weight management objectives. Providing sufficient non-protein energy is essential to preserve lean muscle mass through the protein-sparing effect. In conservative management, the modern Plant-Dominant Low-Protein Diet (PLADO) protocol (0.6–0.8 g protein/kg/day with 50–70% plant-derived sources) harnesses the gut-kidney axis, reduces dietary acid load, and limits bioavailable phosphorus absorption.
Establishing an accurate energy prescription is the single most critical determinant of whether a dietary protein intervention succeeds or fails in nephrology practice. If energy intake is inadequate, even an exquisitely calculated protein prescription will fail to prevent muscle wasting, as amino acids are diverted from protein synthesis to fuel baseline cellular respiration. Furthermore, contemporary renal nutrition has evolved beyond simple caloric and gram counting to prioritize carbohydrate quality, the gut microbiome, and whole-food plant patterns.
1. Energy Requirements Across CKD and ESRD (25–35 kcal/kg/day)
The 2020 KDOQI guidelines recommend that clinicians prescribe 25 to 35 kcal/kg body weight/day for adults with CKD Stages 3–5D who are metabolically stable.
Clinical Determinants of Caloric Needs:
Age: Older, sedentary adults (>=60–65 years) typically require the lower end of the range ( 25 to 30 kcal/kg/day ) due to reductions in basal metabolic rate (BMR) and sarcopenic decreases in metabolically active lean tissue. Younger, active individuals require 30 to 35 kcal/kg/day .
Clinical Goals: Patients presenting with mild protein-energy wasting or those recovering from acute catabolic hospitalizations require 30 to 35 kcal/kg/day (or higher) to achieve cellular repletion and positive nitrogen balance. Overweight or obese individuals require controlled caloric deficits ( 20 to 25 kcal/kg/day ) targeting gradual, non-catabolic weight loss.
Modality Factors (Peritoneal Dialysis): In peritoneal dialysis, glucose absorbed from the dialysate delivers substantial non-oral energy (often 300 to 800+ kcal/day). This dialytic energy must be subtracted from total daily estimated energy expenditure before establishing the oral diet prescription: Prescribed Oral Energy (kcal/day) = Total Energy Requirement (kcal/day) − Dialysate Glucose Absorption (kcal/day) \text{Prescribed Oral Energy (kcal/day)} = \text{Total Energy Requirement (kcal/day)} - \text{Dialysate Glucose Absorption (kcal/day)} Prescribed Oral Energy (kcal/day) = Total Energy Requirement (kcal/day) − Dialysate Glucose Absorption (kcal/day)
The Protein-Sparing Mechanism
Dietary protein cannot be utilized for structural myofibrillar protein synthesis, immunoglobulins, or peptide enzyme synthesis unless non-protein energy requirements (derived from carbohydrates and healthy fats) are fully satisfied. When total caloric intake falls below 25 kcal/kg/day:
Intracellular glycogen stores are rapidly depleted.
Cortisol and glucagon secretion rise, activating skeletal muscle proteolysis.
Glucogenic amino acids (alanine, glutamine, glycine) undergo deamination in the liver to enter the Krebs cycle via pyruvate or oxaloacetate for ATP production.
Nitrogen cleaved from these amino acids is converted to urea, causing a paradoxical surge in Blood Urea Nitrogen (BUN) and metabolic acidosis despite low dietary protein intake.
Sparing dietary protein through adequate caloric provision ensures that amino acids are incorporated into structural tissue, maintaining neutral or positive nitrogen balance.
2. Calculating Energy Needs in Obesity vs. Underweight: Adjusted Body Weight ( a B W aBW a B W )
In nephrology, selecting the correct weight metric to calculate energy and protein prescriptions is critical. Using actual body weight ( W a c t W_{act} W a c t ) in obese patients ( B M I > 30 BMI > 30 BM I > 30 kg/m² or > 120 % >120\% > 120% of Ideal Body Weight [IBW]) substantially overestimates energy needs because adipose tissue has a significantly lower metabolic rate (approximately 4.5 kcal/kg/day) compared to visceral and skeletal muscle tissue (approximately 13 to 20+ kcal/kg/day). Overfeeding obese CKD patients exacerbates hyperglycemia, hypertriglyceridemia, and non-alcoholic fatty liver disease.
Step-by-Step Calculation Protocol:
Calculate Ideal Body Weight (IBW) via the Hamwi Formula:
Adult Males: 106 lbs for the first 5 feet + 6 lbs for each additional inch 106\text{ lbs for the first 5 feet} + 6\text{ lbs for each additional inch} 106 lbs for the first 5 feet + 6 lbs for each additional inch ( ± 10 % \pm 10\% ± 10% for small/large frame size).
Adult Females: 100 lbs for the first 5 feet + 5 lbs for each additional inch 100\text{ lbs for the first 5 feet} + 5\text{ lbs for each additional inch} 100 lbs for the first 5 feet + 5 lbs for each additional inch ( ± 10 % \pm 10\% ± 10% for small/large frame size).
Convert IBW from pounds to kilograms ( lbs ÷ 2.205 \text{lbs} \div 2.205 lbs ÷ 2.205 ).
Determine Percentage of Ideal Body Weight (%IBW): % IBW = ( Actual Edema-Free Weight (kg) IBW (kg) ) × 100 \%\text{IBW} = \left( \frac{\text{Actual Edema-Free Weight (kg)}}{\text{IBW (kg)}} \right) \times 100 % IBW = ( IBW (kg) Actual Edema-Free Weight (kg) ) × 100
If % IBW > 120 % \% \text{IBW} > 120\% % IBW > 120% (or B M I ≥ 30 kg/m 2 BMI \ge 30\text{ kg/m}^2 BM I ≥ 30 kg/m 2 ), the patient is obese, and adjusted body weight must be used.
If % IBW < 90 % \% \text{IBW} < 90\% % IBW < 90% (or B M I < 18.5 kg/m 2 BMI < 18.5\text{ kg/m}^2 BM I < 18.5 kg/m 2 ), the patient is underweight/malnourished, and IBW or target dry weight should be used to promote tissue accretion.
If % IBW \% \text{IBW} % IBW is between 90 % 90\% 90% and 120 % 120\% 120% , use actual edema-free dry weight.
Calculate Adjusted Body Weight ( a B W 0.25 aBW_{0.25} a B W 0.25 ): To account for the low metabolic activity of excess adipose tissue, many clinicians use a 25% adjustment factor (KDOQI 2020 does not mandate a specific weight method): a B W 0.25 = IBW (kg) + 0.25 × [ Actual Edema-Free Weight (kg) − IBW (kg) ] aBW_{0.25} = \text{IBW (kg)} + 0.25 \times \left[ \text{Actual Edema-Free Weight (kg)} - \text{IBW (kg)} \right] a B W 0.25 = IBW (kg) + 0.25 × [ Actual Edema-Free Weight (kg) − IBW (kg) ] (Note: Some protocols apply a 0.40 factor, and the older KDOQI 2000 guideline used a different adjusted edema-free body weight that moves toward standard body weight. State which method you use and apply it consistently.)
3. Carbohydrate Quality, Fiber, and the Gut-Kidney Axis
Contemporary renal nutrition emphasizes carbohydrate quality over simple carbohydrate counting.
Complex vs. Refined Carbohydrates:
Refined Carbohydrates: Simple sugars and processed refined grains promote rapid postprandial glucose surges, advanced glycation end-product (AGE) synthesis, hyperinsulinemia, and systemic oxidative stress.
Complex Carbohydrates: Unrefined grains, legumes, vegetables, and tubers deliver low-glycemic-index starches alongside essential prebiotic dietary fiber.
The Gut-Kidney Axis and Colonic Dysbiosis:
In chronic kidney disease, two pathological factors disrupt normal intestinal homeostasis:
Uremic Milieu: Translocation of circulating urea across the intestinal wall leads to microbial urease hydrolysis, generating massive quantities of ammonium hydroxide ( N H 4 O H NH_4OH N H 4 O H ). This alkalinizes the colonic lumen, damages intestinal tight junction proteins (claudin-1, occludin), and induces gut barrier hyperpermeability ("leaky gut").
Slowed Colonic Transit: Fluid restrictions, sedentary lifestyle, iron supplements, and phosphate binders promote chronic constipation and prolonged transit time.
In this altered environment, the microbiome shifts from beneficial saccharolytic bacteria (Bifidobacteria, Lactobacilli) toward proteolytic species (Enterobacteriaceae, Clostridia). These proteolytic bacteria ferment unabsorbed aromatic amino acids (tyrosine, phenylalanine, tryptophan), generating toxic precursors:
Indole (from tryptophan) → \rightarrow → metabolized by hepatic CYP2E1 and SULT1A1 into Indoxyl Sulfate .
p-Cresol (from tyrosine and phenylalanine) → \rightarrow → sulfated by the liver into p-Cresyl Sulfate .
Trimethylamine (TMA) (from carnitine and choline in red meat/eggs) → \rightarrow → oxidized by hepatic FMO3 into Trimethylamine-N-Oxide (TMAO) .
Indoxyl sulfate and p-cresyl sulfate are protein-bound uremic toxins that cannot be cleared effectively by standard hemodialysis. They induce podocyte injury, accelerate interstitial fibrosis, activate renin-angiotensin-aldosterone signaling, and trigger coronary vascular calcification.
The Protective Role of Dietary Fiber (25–30 g/day):
Prebiotic Substrate: Soluble fiber and resistant starch provide carbon and energy for saccharolytic bacteria.
Short-Chain Fatty Acid (SCFA) Production: Bacterial fermentation of fiber produces acetate, propionate, and butyrate . Butyrate nourishes colonocytes, upregulates tight junction proteins, and decreases systemic endotoxemia.
Acidification of Colonic Lumen: SCFAs lower stool pH, protonating toxic ammonia ( N H 3 NH_3 N H 3 ) into ammonium ( N H 4 + NH_4^+ N H 4 + ). Because charged ammonium cannot diffuse across the gut mucosa, it is trapped and eliminated in the feces.
Bacterial Nitrogen Trapping: Growing saccharolytic bacteria incorporate circulating blood urea nitrogen into their own microbial biomass, diverting nitrogen excretion from failing kidneys to the bowel.
4. The Plant-Dominant Low-Protein Diet (PLADO) Protocol
The Plant-Dominant Low-Protein Diet (PLADO) represents an innovative, evidence-based paradigm in conservative CKD management designed to capitalize on the therapeutic advantages of plant-based nutrition while adhering to safe protein limits.
Core PLADO Prescription:
Total Dietary Protein: 0.60 to 0.80 g/kg body weight/day .
Plant Proportion: More than 50% of total protein (often 50%–70%) from whole, minimally processed plant sources (legumes, tofu, tempeh, intact grains, nuts, seeds, and vegetables).
Energy Intake: 25 to 35 kcal/kg/day to ensure full protein sparing.
Sodium Restriction: <2,000 mg/day (naturally facilitated by eliminating processed animal and canned foods).
Physiological Mechanisms of PLADO:
Blunted Intraglomerular Hyperfiltration: Ingestion of red meat and animal protein causes rapid increases in glucagon, insulin-like growth factor 1 (IGF-1), and renal blood flow, inducing intense afferent arteriolar dilation and single-nephron hyperfiltration. In contrast, isonitrogenous plant protein ingestion induces minimal afferent vasodilation, maintaining low intraglomerular capillary hydrostatic pressure ( P g c P_{gc} P g c ) and blunting proteinuria.
Negative Potential Renal Acid Load (PRAL): Animal proteins are rich in sulfur-containing amino acids (methionine, cysteine), which undergo metabolic oxidation to form sulfuric acid ( H 2 S O 4 H_2SO_4 H 2 S O 4 ). This contributes to Net Endogenous Acid Production (NEAP) and chronic metabolic acidosis. In contrast, whole plant foods are rich in organic potassium and magnesium salts of citrate and malate, which metabolize to bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ), conferring a negative PRAL score. PLADO naturally corrects metabolic acidosis, preserving residual GFR and protecting bone mineral density.
Low Phosphorus Bioavailability via Phytate Binding: In whole grains, legumes, and nuts, phosphorus exists predominantly in the form of phytic acid (myo-inositol 1,2,3,4,5,6-hexakisphosphate) . Humans lack endogenous intestinal phytase enzymes; therefore, gastrointestinal phosphorus absorption from unrefined plant sources is commonly cited at about 20% to 50% . In contrast, organic phosphorus in animal foods is about 40% to 60% bioavailable, and inorganic phosphorus additives in processed foods are 90% to 100% bioavailable. Thus, a high-plant diet delivers substantially less absorbable phosphorus despite comparable total elemental phosphorus content.
Enhanced Fecal Potassium Excretion: High dietary fiber accelerates peristalsis, eliminating constipation. In advanced CKD, the colon undergoes compensatory upregulation of colonic BK (Big Potassium) apical channels. When regular bowel movements are maintained, fecal potassium excretion can account for up to roughly one-third of daily potassium elimination .
Addressing the Hyperkalemia Paradigm:
Historically, renal dietitians discouraged plant-based diets due to fear of hyperkalemia. Modern clinical practice recognizes this approach as overly restrictive and counterproductive:
High-potassium whole plant foods release potassium gradually due to intact cellular fiber matrices.
The alkaline ash of plant foods promotes potassium shifting intracellularly via insulin and bicarbonate-dependent mechanisms.
Rather than eliminating cardioprotective plant foods, clinicians educate patients on low- to moderate-potassium plant proteins (e.g., firm tofu, tempeh, canned rinsed lentils, edamame, hemp seeds).
If mild hyperkalemia develops (serum K > 5.2 K > 5.2 K > 5.2 mEq/L), non-absorbed gastrointestinal potassium binders (patiromer or sodium zirconium cyclosilicate) should be co-prescribed to enable the patient to continue an organ-protective PLADO pattern.
5. Comparative Metabolic Matrix: Animal-Dominant vs. PLADO
Physiological Parameter Animal-Dominant Renal Diet Plant-Dominant Low-Protein Diet (PLADO) Clinical Significance
Protein Source Meat, poultry, dairy, eggs Legumes, tofu, tempeh, grains, nuts Plant amino acids spare intraglomerular pressure
Renal Acid Load (PRAL) Highly positive (+20 to +50 mEq/d) Strongly negative (-10 to -30 mEq/d) Prevents metabolic acidosis and nephron loss
Phosphorus Bioavailability About 40%–60% (organic animal proteins) About 20%–50% (phytate-bound complexes) Mitigates hyperphosphatemia and FGF23 surges
Intraglomerular Hemodynamics Afferent arteriolar vasodilation Blunted vasodilation; preserved P g c P_{gc} P g c Lowers intraglomerular pressure and proteinuria
Colonic Uremic Toxins High Indoxyl Sulfate, p-Cresol, TMAO Suppressed uremic toxin generation Preserves endothelial function and slows CKD
Dietary Fiber Delivery Typically low (<12–15 g/day) High (25–35 g/day) Traps fecal nitrogen and promotes SCFA synthesis
Fecal Potassium Clearance Low (frequent constipation) High (rapid transit, enhanced secretion) Mitigates hyperkalemia risk via bowel clearance